NICE recommends combination Rezolsta (darunavir + cobicistat) to treat HIV-1 virus- Janssen
The National Institute for Health and Care Exellence (NICE) has recommended, once daily, Rezolsta (darunavir + cobicistat) from Janssen for use in combination with other retroviral medications for treatment of adults with HIV-1 virus whose virus does not carry darunavir resistant associated mutations.
Comment: Rezolsta is the most prescribed protease inhibitor in the UK combined with cobicistat (a "booster"). Experts believe that the fixed dose combination could improve adherence by reducing the number of pills to be taken by the patient. Optimal adherence is generally considered to be above 95%, the level required to prevent HIV becoming resistant to medication.
Comment: Clinical data shows that once-daily darunavir/cobicistat, in combination with two nucleotide/nucleoside reverse transcriptase inhibitors, offers effective virological suppression, with virologic response rates over 48 weeks of 81 percent overall and 83 percent in treatment-naïve patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins